Clinical Trial Update: A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 study comparing pharmacokinetics, safety, tolerability, and immunogenicity of HLX15 versus daratumumab in male subjects with multiple myeloma; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• HLX15

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED